Elanco Animal Health Inc (ELAN) is overvalued and Teva- Pharmaceutical Industries Ltd (TEVA) is overvalued.
Both trade above our estimate of their intrinsic value. TEVA is the closer of the two: -92%, against -364% for ELAN.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 10.6% values the shares at $4.94; the price of $22.93 is 364% above that value, and 71% of that value comes from beyond year five.
Leak Score 0/100 on 2 of 12 signals
Discounting its cash flows at 8.5% (average of 3 methods) values the shares at $20.57; the price of $39.52 is 92% above that value, and 77% of that value comes from beyond year five.
Leak Score 0/100 on 3 of 12 signals
| Metric | ELAN | TEVA |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Price | $22.93 | $39.52 |
| Intrinsic value | $4.94 | $20.57 |
| Margin of safety | -364% | -92% |
| Leak Score | 0/100 (2/12) | 0/100 (3/12) |
| Market cap | $11.5B | $46.1B |
| Revenue growth, 5 years | 7.6% | 0.8% |
| Operating margin | 6.6% | 18.8% |
| Net margin | -4.0% | 4.1% |
| Return on equity | -3.0% | 9.7% |
| Debt to equity | 0.59 | 2.18 |
| P/E | — | 65.9x |
| Forward P/E | 17.9x | 12.9x |
| P/B | 1.7x | 5.9x |